Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 7/20 | 0.79 |
| ▸ | TSHR | P16473 | 3/20 | 0.79 |
| ▸ | LMNA | P02545 | 2/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.79 |
| ▸ | THPO | P40225 | 1/20 | 0.79 |
| ▸ | STAT6 | P42226 | 1/20 | 0.79 |
| ▸ | BLM | P54132 | 1/20 | 0.79 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CTSV | O60911 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dubinidine SCHEMBL29652222 | 0.88 | CYP1A2 (1.00) | CYP1A2TSHRLMNACYP3A4THPO | |
| SCHEMBL29374386 | 0.83 | MEN1 (1.00) | CYP1A2TSHRLMNACYP3A4THPO | |
| SCHEMBL30633046 | 0.72 | LMNA (0.53) | CYP1A2TSHRLMNACYP3A4THPO | |
| SCHEMBL19407335 | 0.69 | CYP1A2 (0.66) | CYP1A2TSHRLMNACYP3A4THPO | |
| SCHEMBL1408391 | 0.66 | POLB (1.00) | TSHRLMNAMEN1KMT2APOLB | |
| SCHEMBL28063855 | 0.64 | POLB (0.56) | CYP1A2TSHRLMNACYP3A4THPO | |
| SCHEMBL10286526 | 0.62 | ACHE (0.65) | CYP1A2TSHRLMNACYP3A4THPO | |
| SCHEMBL2879866 | 0.62 | POLB (0.68) | LMNAMEN1KMT2APOLBKDM4E | |
| SCHEMBL5086577 | 0.62 | POLB (0.61) | CYP1A2TSHRLMNACYP3A4THPO | |
| SCHEMBL9694998 | 0.60 | POLB (0.70) | CYP1A2LMNACYP3A4KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250032448-A1 | COMPOUND FOR USE IN THE TREATMENT AND/OR PREVENTION OF PARASITIC MEDIATED DISEASES | KOH, Hwee Ling (SG) | 2025-01-30 | — | — | US | disclosed |
| US-12144797-B2 | Compound for use in the treatment and/or prevention of parasitic mediated diseases | KOH, Hwee Ling (SG) | 2024-11-19 | — | — | US | disclosed |
| CN-110463468-A | One kind, which has, prevents and treats dermopathic Chinese herbal medicine plant training system and device | HUNAN JIUCENGTAI ENVIRONMENT TECH CO LTD | 2019-11-19 | — | — | CN | disclosed |
| CN-105418729-A | Limonin compound for treating chronic granulocytic leukemia and preparation method thereof | WU JINFENG | 2016-03-23 | — | — | CN | disclosed |
| CN-105153263-A | New limonin compound as well as preparation method and medical application thereof | ZHOU WUXIAN | 2015-12-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12144797-B2 | Compound for use in the treatment and/or prevention of parasitic mediated diseases | ICMT, ALG3, PFN1 | CYP1A2 123/4885TSHR 4854/4885LMNA 88/4885 |
| US-20250032448-A1 | COMPOUND FOR USE IN THE TREATMENT AND/OR PREVENTION OF PARASITIC MEDIATED DISEASES | EPX, PKD2, MPO | CYP1A2 302/4885TSHR 2855/4885LMNA 1112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.